Zylox-Tonbridge Medical Technology Co., Ltd. (stock code: 02190.HK, “ZYLOXTB”) filed a Next Day Disclosure Return on 18 March 2026, detailing a share buyback executed on the same date.

The company repurchased 100,000 H shares on the Hong Kong Stock Exchange at prices ranging from HK$21.26 to HK$22.18, representing a volume-weighted average of HK$21.82 per share. Total consideration paid amounted to HK$2.18 million. All repurchased shares have been retained as treasury shares; none were cancelled.

Following the transaction, the number of issued shares (excluding treasury shares) fell 0.03 % from 329.50 million to 329.40 million, while treasury shares increased from 6.85 million to 6.95 million. Total issued shares remained unchanged at 336.35 million.

The buyback was carried out under the general mandate granted on 30 May 2025, which authorises repurchases of up to 31.96 million shares. Cumulative repurchases under this mandate now stand at 4.13 million shares, equating to 1.26 % of the company’s issued share capital at the mandate date.

Under Hong Kong listing rules, ZYLOXTB is subject to a moratorium on issuing new shares or disposing of treasury shares until 17 April 2026. The board confirmed that the repurchase complied with all applicable regulations and internal authorisations.